Art

J-GLOBAL ID：201902284123568044   Reference number：19A0108257

Serum creatine kinase elevation by atypical antipsychotics and genetic polymorphisms of the 5-HT2A receptor and the cytochrome P450 2D6: a preliminary finding

非定型抗精神病薬による血清クレアチンキナーゼの上昇と5-HT2A受容体およびチトクロームP450 2D6の遺伝的多型:予備的知見

Author (5)： Nakamura Akifumi (Department of Neuropsychiatry, Graduate School of Medicine, University of the Ryukyus) ,  Mihara Kazuo (Department of Neuropsychiatry, Graduate School of Medicine, University of the Ryukyus) ,  Nagai Goyo (Department of Neuropsychiatry, Graduate School of Medicine, University of the Ryukyus) ,  Sakumoto Noboru (Department of Neuropsychiatry, Graduate School of Medicine, University of the Ryukyus) ,  Kondo Tsuyoshi (Department of Neuropsychiatry, Graduate School of Medicine, University of the Ryukyus)
Material： Clinical Neuropsychopharmacology and Therapeutics (Web)  (Clin Neuropsychopharmacology Ther (Web))
Volume： 9  Page： 3-6(J-STAGE)  Publication year： 2018 
JST Material Number： U0228A  ISSN： 1884-8826  Document type： Article
Article type： 短報  Country of issue： Japan (JPN)  Language： ENGLISH (EN)

Thesaurus term： *antipsychotic agent ,...
Semi thesaurus term： *Receptor, Serotonin, 5-HT2A ,...

Register(free) or Log In to access     To see more with JDream III (charged).   {{ this.onShowAbsJLink("http://jdream3.com/lp/jglobal/index.html?docNo=19A0108257&from=J-GLOBAL&jstjournalNo=U0228A") }}

Author keywords (4)： creatine kinase ,  atypical antipsychotics ,  5-HT2A T102C and His452Try polymorphisms ,  CYP2D6 polymorphism

JST classification (2)： Clinical application of psychotropic drugs  (GW03110J) ,  Drug therapy(=pharmacotherapy)for mental disorders  (GR04020D)

Reference (7)：

• [1] Laoutidis ZG, Kioulos KT. Antipsychotic-induced elevation of creatine kinase: a systematic review of the literature and recommendations for the clinical practice. Psychopharmacology 2014; 231:4255-4270.
• [2] Hermesh H, Manor I, Shiloh R, Aizenberg D, Benjamini Y, Munitz H, Weizmen A. High serum creatinine kinase level: possible risk factor for neuroleptic malignant syndrome. J Clin Psychopharmacol 2002; 22: 252-256.
• [3] Serretti A, Drago A, De Ronchi D. HTR2A gene variations and psychiatric disorders: a review of current literature and selection of SNPs for future studies. Curr Med Chem 2007; 14: 2053-2069.
• [4] Teh LK, Bertilsson L. Pharmacogenetics of CYP2D6: molecular genetics, interethnic differences and clinical importance. Drug Metab Pharmacokinet 2012; 27: 55-67.
• [5] Ohara K, Nagai M, Tani K, Tsukamoto T, Ohara K. Schizophrenia and the serotonin-2A receptor promoter polymorphism. Psychiat Res 1999; 85: 221-224.

Terms in the title (6)： 非定型抗精神病薬 ,  血清 ,  クレアチンキナーゼ ,  5-HT2A受容体 ,  チトクロームP450 ,  遺伝的多型